Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Engineered materials for in vivo delivery of genome-editing machinery


Genome-editing technologies, such as CRISPR–Cas9, are promising for treating otherwise incurable genetic diseases. Great progress has been made for ex vivo genome editing; however, major bottlenecks exist in the development of efficient, safe and targetable in vivo delivery systems, which are needed for the treatment of many diseases. To achieve high efficacy and safety in therapeutic, in vivo genome editing, editing activities must be controlled spatially and temporally in the body, which requires novel materials, delivery strategies and control mechanisms. Thus, there is currently a tremendous opportunity for the biomaterials research community to develop in vivo delivery systems that overcome the problems of low editing efficiency, off-targeting effect, safety, and cell and tissue specificity. In this Review, we summarize delivery approaches and provide perspectives on the challenges and possible solutions, aiming to stimulate further development of engineered materials for in vivo delivery of genome-editing machinery.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Biological barriers to in vivo delivery from systemic circulation to cell nucleus.
Fig. 2: Viral base in vivo delivery of genome-editing machinery.
Fig. 3: Examples of material systems for in vivo delivery of genome-editing machinery.
Fig. 4: Delivery strategies to overcome challenges in the efficiency, specificity and safety of in vivo delivery of genome-editing machinery.


  1. 1.

    Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397–405 (2013).

    CAS  Google Scholar 

  2. 2.

    Miller, J., McLachlan, A. D. & Klug, A. Repetitive zinc-binding domains in the protein transcription factor IIIA from Xenopus oocytes. EMBO J. 4, 1609–1614 (1985).

    CAS  Google Scholar 

  3. 3.

    Kim, Y. G., Cha, J. & Chandrasegaran, S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. USA 93, 1156–1160 (1996).

    CAS  Google Scholar 

  4. 4.

    Christian, M. et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757–761 (2010).

    CAS  Google Scholar 

  5. 5.

    Yin, H., Kauffman, K. J. & Anderson, D. G. Delivery technologies for genome editing. Nat. Rev. Drug Discov. 16, 387–399 (2017).

    CAS  Google Scholar 

  6. 6.

    Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

    CAS  Google Scholar 

  7. 7.

    Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).

    CAS  Google Scholar 

  8. 8.

    Bolotin, A., Quinquis, B., Sorokin, A. & Ehrlich, S. D. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 151, 2551–2561 (2005).

    CAS  Google Scholar 

  9. 9.

    Mojica, F. J., Diez-Villaseñor, C., García-Martínez, J. & Soria, E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J. Mol. Evol. 60, 174–182 (2005).

    CAS  Google Scholar 

  10. 10.

    Pourcel, C., Salvignol, G. & Vergnaud, G. CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology 151, 653–663 (2005).

    CAS  Google Scholar 

  11. 11.

    Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 32, 347–355 (2014).

    CAS  Google Scholar 

  12. 12.

    Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121–131 (2015).

    CAS  Google Scholar 

  13. 13.

    Lee, C. M., Cradick, T. J. & Bao, G. The Neisseria meningitidis CRISPR-Cas9 system enables specific genome editing in mammalian cells. Mol. Ther. 24, 645–654 (2016).

    CAS  Google Scholar 

  14. 14.

    Lee, C. M., Cradick, T. J., Fine, E. J. & Bao, G. Nuclease target site selection for maximizing on-target activity and minimizing off-target effects in genome editing. Mol Ther. 24, 475–487 (2016).

    CAS  Google Scholar 

  15. 15.

    Cradick, T. J., Fine, E. J., Antico, C. J. & Bao, G. CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 41, 9584–9592 (2013).

    CAS  Google Scholar 

  16. 16.

    Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822–826 (2013).

    CAS  Google Scholar 

  17. 17.

    Lin, Y. et al. CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res. 42, 7473–7485 (2014).

    CAS  Google Scholar 

  18. 18.

    Hou, Z. et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc. Natl. Acad. Sci. USA 110, 15644–15649 (2013).

    CAS  Google Scholar 

  19. 19.

    Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015).

    CAS  Google Scholar 

  20. 20.

    Kim, E. et al. In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni. Nat. Commun. 8, 14500 (2017).

    CAS  Google Scholar 

  21. 21.

    Zetsche, B. et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163, 759–771 (2015).

    CAS  Google Scholar 

  22. 22.

    Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016).

    CAS  Google Scholar 

  23. 23.

    Nishida, K. et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 353, aaf8729 (2016).

    Google Scholar 

  24. 24.

    Gaudelli, N. M. et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature 551, 464–471 (2017).

    CAS  Google Scholar 

  25. 25.

    Kim, Y. B. et al. Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. Nat. Biotechnol. 35, 371–376 (2017).

    CAS  Google Scholar 

  26. 26.

    Zuo, E. et al. Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science 364, (289–292 (2019).

    Google Scholar 

  27. 27.

    Jin, S. et al. Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice. Science 364, (292–295 (2019).

    Google Scholar 

  28. 28.

    Villiger, L. et al. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice. Nat. Med. 24, 1519–1525 (2018).

    CAS  Google Scholar 

  29. 29.

    Shmakov, S. et al. Discovery and functional characterization of diverse class 2 CRISPR-Cas systems. Mol. Cell 60, 385–397 (2015).

    CAS  Google Scholar 

  30. 30.

    Abudayyeh, O. O. et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science 353, aaf5573 (2016).

    Google Scholar 

  31. 31.

    Abudayyeh, O. O. et al. RNA targeting with CRISPR–Cas13. Nature 550, 280–284 (2017).

    Google Scholar 

  32. 32.

    Qu, L. et al. Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. Nat. Biotechnol. 37, 1059–1069 (2019).

    CAS  Google Scholar 

  33. 33.

    Dever, D. P. et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature 539, 384–389 (2016).

    CAS  Google Scholar 

  34. 34.

    Martin, R. M. et al. Highly efficient and marker-free genome editing of human pluripotent stem cells by CRISPR-Cas9 RNP and AAV6 donor-mediated homologous recombination. Cell Stem Cell 24, 821–828 (2019).

    CAS  Google Scholar 

  35. 35.

    Walkey, C. D., Olsen, J. B., Guo, H., Emili, A. & Chan, W. C. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 134, 2139–2147 (2012).

    CAS  Google Scholar 

  36. 36.

    Walkey, C. D. et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 8, 2439–2455 (2014).

    CAS  Google Scholar 

  37. 37.

    Charlesworth, C. T. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med. 25, 249–254 (2019).

    CAS  Google Scholar 

  38. 38.

    Wagner, D. L. et al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat. Med. 25, 242–248 (2019).

    CAS  Google Scholar 

  39. 39.

    Komarova, Y. & Malik, A. B. Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annu. Rev. Physiol. 72, 463–493 (2010).

    CAS  Google Scholar 

  40. 40.

    Dreher, M. R. et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 98, 335–344 (2006).

    CAS  Google Scholar 

  41. 41.

    Yuan, F., Krol, A. & Tong, S. Available space and extracellular transport of macromolecules: effects of pore size and connectedness. Ann. Biomed. Eng. 29, 1150–1158 (2001).

    CAS  Google Scholar 

  42. 42.

    Orsi, M., Sanderson, W. E. & Essex, J. W. Permeability of small molecules through a lipid bilayer: a multiscale simulation study. J. Phys. Chem. B 113, 12019–12029 (2009).

    CAS  Google Scholar 

  43. 43.

    Zhang, S., Gao, H. & Bao, G. Physical principles of nanoparticle cellular endocytosis. ACS Nano 9, 8655–8671 (2015).

    CAS  Google Scholar 

  44. 44.

    Vakulskas, C. A. et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat. Med. 24, 1216–1224 (2018).

    CAS  Google Scholar 

  45. 45.

    Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M. & Abedi, M. R. Gene therapy clinical trials worldwide to 2017: An update. J. Gene Med. 20, e3015 (2018).

    Google Scholar 

  46. 46.

    Yanik, M. et al. In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies. Prog. Retin. Eye Res. 56, 1–18 (2017).

    CAS  Google Scholar 

  47. 47.

    Swiech, L. et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 33, 102–106 (2015).

    CAS  Google Scholar 

  48. 48.

    Long, C. et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351, 400–403 (2016).

    CAS  Google Scholar 

  49. 49.

    Nelson, C. E. et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat. Med. 25, 427–432 (2019).

    CAS  Google Scholar 

  50. 50.

    Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407–411 (2016).

    CAS  Google Scholar 

  51. 51.

    Yang, Y. et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat. Biotechnol. 34, 334–338 (2016).

    CAS  Google Scholar 

  52. 52.

    Hakim, C. H. et al. AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice. JCI Insight 3, e124297 (2018).

    Google Scholar 

  53. 53.

    Bak, R. O. & Porteus, M. H. CRISPR-mediated integration of large gene cassettes using AAV donor vectors. Cell Rep. 20, 750–756 (2017).

    CAS  Google Scholar 

  54. 54.

    Maddalena, A. et al. Triple vectors expand AAV transfer capacity in the retina. Mol Ther 26, 524–541 (2018).

    CAS  Google Scholar 

  55. 55.

    Zincarelli, C., Soltys, S., Rengo, G. & Rabinowitz, J. E. Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073–1080 (2008).

    CAS  Google Scholar 

  56. 56.

    Baruteau, J., Waddington, S. N., Alexander, I. E. & Gissen, P. Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. J. Inherit. Metab. Dis. 40, 497–517 (2017).

    CAS  Google Scholar 

  57. 57.

    Wu, Z., Yang, H. & Colosi, P. Effect of genome size on AAV vector packaging. Mol. Ther. 18, 80–86 (2010).

    CAS  Google Scholar 

  58. 58.

    Chen, X. & Goncalves, M. A. Engineered viruses as genome editing devices. Mol. Ther. 24, 447–457 (2016).

    CAS  Google Scholar 

  59. 59.

    Dai, X. et al. One-step generation of modular CAR-T cells with AAV-Cpf1. Nat. Methods 16, 247–254 (2019).

    CAS  Google Scholar 

  60. 60.

    Sun, L., Li, J. & Xiao, X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat. Med. 6, 599–602 (2000).

    CAS  Google Scholar 

  61. 61.

    Chew, W. L. et al. A multifunctional AAV-CRISPR-Cas9 and its host response. Nat. Methods 13, 868–874 (2016).

    CAS  Google Scholar 

  62. 62.

    Schucht, R. et al. A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors. Mol. Ther. 14, 285–292 (2006).

    CAS  Google Scholar 

  63. 63.

    Follenzi, A., Sabatino, G., Lombardo, A., Boccaccio, C. & Naldini, L. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum. Gene Ther. 13, 243–260 (2002).

    CAS  Google Scholar 

  64. 64.

    Blömer, U. et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71, 6641–6649 (1997).

    Google Scholar 

  65. 65.

    Abordo-Adesida, E. et al. Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum. Gene Ther. 16, 741–751 (2005).

    CAS  Google Scholar 

  66. 66.

    Wanisch, K. & Yanez-Munoz, R. J. Integration-deficient lentiviral vectors: a slow coming of age. Mol. Ther. 17, 1316–1332 (2009).

    CAS  Google Scholar 

  67. 67.

    Heckl, D. et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat. Biotechnol. 32, 941–946 (2014).

    CAS  Google Scholar 

  68. 68.

    Platt, R. J. et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440–455 (2014).

    CAS  Google Scholar 

  69. 69.

    LaFleur, M. W. et al. A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system. Nat. Commun. 10, 1668 (2019).

    Google Scholar 

  70. 70.

    Mangeot, P. E. et al. Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins. Nat Commun 10, 45 (2019).

    Google Scholar 

  71. 71.

    Candolfi, M. et al. Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol. Ther. 14, 371–381 (2006).

    CAS  Google Scholar 

  72. 72.

    Ding, Q. et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ. Res. 115, 488–492 (2014).

    CAS  Google Scholar 

  73. 73.

    Bjursell, M. et al. Therapeutic genome editing with CRISPR/Cas9 in a humanized mouse model ameliorates α1-antitrypsin deficiency phenotype. EBioMedicine 29, 104–111 (2018).

    Google Scholar 

  74. 74.

    Chadwick, A. C., Wang, X. & Musunuru, K. In vivo base editing of PCSK9 (proprotein convertase subtilisin/kexin type 9) as a therapeutic alternative to genome editing. Arterioscler. Thromb. Vasc. Biol. 37, 1741–1747 (2017).

    CAS  Google Scholar 

  75. 75.

    Li, A. et al. A self-deleting AAV-CRISPR system for in vivo genome editing. Mol. Ther. Methods Clin. Dev. 12, 111–122 (2019).

    CAS  Google Scholar 

  76. 76.

    Boutin, S. et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704–712 (2010).

    CAS  Google Scholar 

  77. 77.

    Colella, P., Ronzitti, G. & Mingozzi, F. Emerging issues in AAV-mediated in vivo gene therapy. Mol. Ther. Methods Clin. Dev. 8, 87–104 (2018).

    CAS  Google Scholar 

  78. 78.

    Meliani, A. et al. Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system. Hum. Gene Ther. Methods 26, 45–53 (2015).

    CAS  Google Scholar 

  79. 79.

    Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713–1722 (2017).

    CAS  Google Scholar 

  80. 80.

    Vandamme, C., Adjali, O. & Mingozzi, F. Unraveling the complex story of immune responses to AAV vectors trial after trial. Hum. Gene Ther. 28, 1061–1074 (2017).

    CAS  Google Scholar 

  81. 81.

    Hinderer, C. et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene Ther. 29, 285–298 (2018).

    CAS  Google Scholar 

  82. 82.

    van der Loo, J. C. & Wright, J. F. Progress and challenges in viral vector manufacturing. Hum. Mol. Genet. 25, R42–R52 (2016).

    Google Scholar 

  83. 83.

    Getts, D. R., Shea, L. D., Miller, S. D. & King, N. J. Harnessing nanoparticles for immune modulation. Trends Immunol. 36, 419–427 (2015).

    CAS  Google Scholar 

  84. 84.

    Wang, H. X. et al. CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chem. Rev. 117, 9874–9906 (2017).

    CAS  Google Scholar 

  85. 85.

    Zuris, J. A. et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33, 73–80 (2015).

    CAS  Google Scholar 

  86. 86.

    Gao, X. et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature 553, 217–221 (2018).

    CAS  Google Scholar 

  87. 87.

    Chen, Z. et al. Targeted delivery of CRISPR/Cas9-mediated cancer gene therapy via liposome-templated hydrogel nanoparticles. Adv. Funct. Mater. 27, 1703036 (2017).

    Google Scholar 

  88. 88.

    Lee, K. et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat. Biomed. Eng. 1, 889–901 (2017).

    CAS  Google Scholar 

  89. 89.

    Lee, B. et al. Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours. Nat. Biomed. Eng. 2, 497–507 (2018).

    CAS  Google Scholar 

  90. 90.

    Pan, Y. et al. Near-infrared upconversion-activated CRISPR-Cas9 system: A remote-controlled gene editing platform. Sci. Adv. 5, eaav7199 (2019).

    CAS  Google Scholar 

  91. 91.

    Lao, Y. H. et al. HPV oncogene manipulation using nonvirally delivered CRISPR/Cas9 or Natronobacterium gregoryi Argonaute. Adv. Sci. 5, 1700540 (2018).

    Google Scholar 

  92. 92.

    Wang, H. X. et al. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide. Proc. Natl. Acad. Sci. USA 115, 4903–4908 (2018).

    CAS  Google Scholar 

  93. 93.

    Jiang, C. et al. A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo. Cell Res 27, 440–443 (2017).

    CAS  Google Scholar 

  94. 94.

    Yin, H. et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol. 34, 328–333 (2016).

    CAS  Google Scholar 

  95. 95.

    Zhu, H. et al. Spatial control of in vivo CRISPR-Cas9 genome editing via nanomagnets. Nat. Biomed. Eng. 3, 126–136 (2019).

    CAS  Google Scholar 

  96. 96.

    Nesargikar, P. N., Spiller, B. & Chavez, R. The complement system: history, pathways, cascade and inhibitors. Eur. J. Microbiol. Immunol. (Bp) 2, 103–111 (2012).

    CAS  Google Scholar 

  97. 97.

    Oh, P. et al. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat. Biotechnol. 25, 327–337 (2007).

    CAS  Google Scholar 

  98. 98.

    Qiu, Y. et al. Magnetic forces enable controlled drug delivery by disrupting endothelial cell-cell junctions. Nat. Commun. 8, 15594 (2017).

    CAS  Google Scholar 

  99. 99.

    Rapoport, S. I. Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy. Expert. Opin. Investig. Drugs 10, 1809–1818 (2001).

    CAS  Google Scholar 

  100. 100.

    Timbie, K. F., Mead, B. P. & Price, R. J. Drug and gene delivery across the blood–brain barrier with focused ultrasound. J. Control. Release 219, 61–75 (2015).

    CAS  Google Scholar 

  101. 101.

    Monsky, W. L. et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 59, 4129–4135 (1999).

    CAS  Google Scholar 

  102. 102.

    Wong, K. M., Horton, K. J., Coveler, A. L., Hingorani, S. R. & Harris, W. P. Targeting the tumor stroma: the biology and clinical development of pegylated recombinant human hyaluronidase (PEGPH20). Curr. Oncol. Rep. 19, 47 (2017).

    Google Scholar 

  103. 103.

    Senturk, S. et al. Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization. Nat. Commun. 8, 14370 (2017).

    CAS  Google Scholar 

  104. 104.

    Maji, B. et al. A high-throughput platform to identify small-molecule inhibitors of CRISPR-Cas9. Cell 177, 1067–1079 (2019).

    CAS  Google Scholar 

  105. 105.

    Zhou, X. X. et al. A single-chain photoswitchable CRISPR-Cas9 architecture for light-inducible gene editing and transcription. ACS Chem. Biol. 13, 443–448 (2018).

    CAS  Google Scholar 

  106. 106.

    Nihongaki, Y., Kawano, F., Nakajima, T. & Sato, M. Photoactivatable CRISPR-Cas9 for optogenetic genome editing. Nat. Biotechnol. 33, 755–760 (2015).

    CAS  Google Scholar 

  107. 107.

    Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).

    CAS  Google Scholar 

  108. 108.

    Joshi, M., Pathak, S., Sharma, S. & Patravale, V. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int. J. Pharm. 364, 119–126 (2008).

    CAS  Google Scholar 

  109. 109.

    Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).

    CAS  Google Scholar 

  110. 110.

    Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C. & Doudna, J. A. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507, 62–67 (2014).

    CAS  Google Scholar 

  111. 111.

    DeWitt, M. A. et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci. Transl. Med. 8, 360ra134 (2016).

    Google Scholar 

  112. 112.

    Capecchi, M. R. Altering the genome by homologous recombination. Science 244, 1288–1292 (1989).

    CAS  Google Scholar 

  113. 113.

    Rivera-Torres, N., Banas, K., Bialk, P., Bloh, K. M. & Kmiec, E. B. Insertional mutagenesis by CRISPR/Cas9 ribonucleoprotein gene editing in cells targeted for point mutation repair directed by short single-stranded DNA oligonucleotides. PLoS One 12, e0169350 (2017).

    Google Scholar 

  114. 114.

    Park, S. H. et al. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. Nucleic Acids Res. 47, 7955–7972 (2019).

    Google Scholar 

  115. 115.

    Byrne, S. M., Ortiz, L., Mali, P., Aach, J. & Church, G. M. Multi-kilobase homozygous targeted gene replacement in human induced pluripotent stem cells. Nucleic Acids Res. 43, e21 (2015).

    Google Scholar 

  116. 116.

    Eoh, J. & Gu, L. Biomaterials as vectors for the delivery of CRISPR-Cas9. Biomater. Sci. 7, 1240–1261 (2019).

    CAS  Google Scholar 

  117. 117.

    Yin, H. et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat. Biotechnol. 35, 1179–1187 (2017).

    CAS  Google Scholar 

  118. 118.

    Lu, B. et al. Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing. Nucleic Acids Res. 47, e44 (2019).

    Google Scholar 

Download references


This work was supported by the Cancer Prevention and Research Institute of Texas (RR140081 to G.B.), the National Institutes of Health (R01EB026893 to S.T., UG3TR002863 to K.L. and UG3HL151545 to G.B.) and Defense Advanced Research Projects Agency (HR0011-19-2-0009 to K.L.).

Author information




All authors contributed to the discussion and writing of this manuscript.

Corresponding author

Correspondence to Gang Bao.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tong, S., Moyo, B., Lee, C.M. et al. Engineered materials for in vivo delivery of genome-editing machinery. Nat Rev Mater 4, 726–737 (2019).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing